Technical Analysis for FRX - Fennec Pharmaceuticals Inc.

Grade Last Price % Change Price Change
C 12.820 -6.90% -0.950
FRX closed down 6.9 percent on Friday, April 19, 2024, on 48 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Earnings due: May 9
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Gapped Down Weakness 0.00%
Fell Below 20 DMA Bearish -6.90%
Narrow Range Bar Range Contraction -6.90%
Gapped Down Weakness -6.90%
Narrow Range Bar Range Contraction -10.47%
Gapped Up Strength -10.47%
MACD Bearish Signal Line Cross Bearish -9.72%
Narrow Range Bar Range Contraction -9.72%

   Recent Intraday Alerts

Alert Time
Down 1 ATR 3 days ago
Fell Below Previous Day's Low 3 days ago
Down 3% 3 days ago
Down 2% 3 days ago
Down 1% 3 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Fennec Pharmaceuticals Inc. Description

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pharma Pharmaceutical Clinic Disease Cancer RTT Pharmaceuticals Therapy Clinical Trial Oncology Biopharmaceutical Cancers Tumor Blastoma Tumors Brain Tumor Childhood Neoplasms

Is FRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.43
52 Week Low 6.7
Average Volume 825
200-Day Moving Average 12.167
50-Day Moving Average 13.374
20-Day Moving Average 14.012
10-Day Moving Average 14.389
Average True Range 0.390
RSI (14) 39.39
ADX 24.52
+DI 36.762
-DI 50.383
Chandelier Exit (Long, 3 ATRs) 14.031
Chandelier Exit (Short, 3 ATRs) 13.189
Upper Bollinger Bands 15.785
Lower Bollinger Band 12.238
Percent B (%b) 0.16
BandWidth 25.313
MACD Line 0.209
MACD Signal Line 0.398
MACD Histogram -0.1891
Fundamentals Value
Market Cap 330.88 Million
Num Shares 25.8 Million
EPS -0.67
Price-to-Earnings (P/E) Ratio -19.16
Price-to-Sales 0.00
Price-to-Book 6.53
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.835
Resistance 3 (R3) 12.833 12.827 12.833
Resistance 2 (R2) 12.827 12.823 12.828 12.832
Resistance 1 (R1) 12.823 12.820 12.825 12.825 12.831
Pivot Point 12.817 12.817 12.818 12.818 12.817
Support 1 (S1) 12.813 12.813 12.815 12.815 12.809
Support 2 (S2) 12.807 12.810 12.808 12.808
Support 3 (S3) 12.803 12.807 12.808
Support 4 (S4) 12.805